The designation for HCB101covers all forms of gastric cancer, including advanced gastric adenocarcinoma in both HER2-positive and HER2-negative patients
The recommendation is based on new data from continuous safety monitoring of medicines in the EU
Dawson joins Roche from the Peter MacCallum Cancer Centre, where he serves as Associate Director of Research
Ind-Ra expects chronic therapies to outpace IPM as compliance improves and lifestyle diseases rise
If approved, Ameluz would become the first and only photodynamic therapy (PDT) photosensitizer for sBCC in the US
MYC, a master regulator of oncogenic transcription, drives multiple high-burden cancers but has long eluded direct pharmacologic control
The approval marks a major advance in targeted treatment for this rare, chronic autoimmune disease, offering twice-yearly maintenance dosing after two initial loading doses
Bocunebart works by blocking pituitary adenylate cyclase-activating polypeptide
Subscribe To Our Newsletter & Stay Updated
